Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
34,876,487
-
Share change
-
+2,988,468
-
Total reported value
-
$605,788,469
-
Put/Call ratio
-
101%
-
Price per share
-
$17.37
-
Number of holders
-
134
-
Value change
-
+$53,667,586
-
Number of buys
-
67
-
Number of sells
-
53
Institutional Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q3 2023
As of 30 Sep 2023,
Kiniksa Pharmaceuticals Intern - COM (KNSA) was held by
134 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,876,487 shares.
The largest 10 holders included
BlackRock Inc., Rubric Capital Management LP, VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, Fairmount Funds Management LLC, STATE STREET CORP, Pictet Asset Management Holding SA, MORGAN STANLEY, GOLDMAN SACHS GROUP INC, and ArrowMark Colorado Holdings LLC.
This page lists
134
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.